The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions

Daniella Kovacsics, Izabel Patik, C. Özvegy-Laczka

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Introduction: The in vivo fate and effectiveness of a drug depends highly on its absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Organic anion transporting polypeptides (OATPs) are membrane proteins involved in the cellular uptake of various organic compounds, including clinically used drugs. Since OATPs are significant players in drug absorption and distribution, modulation of OATP function via pharmacotherapy with OATP substrates/inhibitors, or modulation of their expression, affects drug pharmacokinetics. Given their cancer-specific expression, OATPs may also be considered anticancer drug targets. Areas covered: We describe the human OATP family, discussing clinically relevant consequences of altered OATP function. We offer a critical analysis of published data on the role of OATPs in ADME and in drug–drug interactions, especially focusing on OATP1A2, 1B1, 1B3 and 2B1. Expert opinion: Four members of the OATP family, 1A2, 1B1, 1B3 and 2B1, have been characterized in detail. As biochemical and pharmacological knowledge on the other OATPs is lacking, it seems timely to direct research efforts towards developing the experimental framework needed to investigate the transport mechanism and substrate specificity of the poorly described OATPs. In addition, elucidating the role of OATPs in tumor development and therapy response are critical avenues for further research.

Original languageEnglish
Pages (from-to)409-424
Number of pages16
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume13
Issue number4
DOIs
Publication statusPublished - Apr 3 2017

Fingerprint

Drug interactions
Drug Interactions
Anions
Peptides
Pharmaceutical Preparations
Modulation
Drug therapy
Pharmacokinetics
Expert Testimony
Substrates
Substrate Specificity
Organic compounds
Research
Metabolism
Toxicity
Tumors

Keywords

  • ADME
  • Drug-drug interaction
  • GWAS
  • hepatic clearance
  • intestinal absorption
  • organic anion transporting polypeptides
  • pharmacogenetics
  • pharmacokinetics

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions. / Kovacsics, Daniella; Patik, Izabel; Özvegy-Laczka, C.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 13, No. 4, 03.04.2017, p. 409-424.

Research output: Contribution to journalReview article

@article{f7c320fa51cb47cdb19c640022fbc9e5,
title = "The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions",
abstract = "Introduction: The in vivo fate and effectiveness of a drug depends highly on its absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Organic anion transporting polypeptides (OATPs) are membrane proteins involved in the cellular uptake of various organic compounds, including clinically used drugs. Since OATPs are significant players in drug absorption and distribution, modulation of OATP function via pharmacotherapy with OATP substrates/inhibitors, or modulation of their expression, affects drug pharmacokinetics. Given their cancer-specific expression, OATPs may also be considered anticancer drug targets. Areas covered: We describe the human OATP family, discussing clinically relevant consequences of altered OATP function. We offer a critical analysis of published data on the role of OATPs in ADME and in drug–drug interactions, especially focusing on OATP1A2, 1B1, 1B3 and 2B1. Expert opinion: Four members of the OATP family, 1A2, 1B1, 1B3 and 2B1, have been characterized in detail. As biochemical and pharmacological knowledge on the other OATPs is lacking, it seems timely to direct research efforts towards developing the experimental framework needed to investigate the transport mechanism and substrate specificity of the poorly described OATPs. In addition, elucidating the role of OATPs in tumor development and therapy response are critical avenues for further research.",
keywords = "ADME, Drug-drug interaction, GWAS, hepatic clearance, intestinal absorption, organic anion transporting polypeptides, pharmacogenetics, pharmacokinetics",
author = "Daniella Kovacsics and Izabel Patik and C. {\"O}zvegy-Laczka",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/17425255.2017.1253679",
language = "English",
volume = "13",
pages = "409--424",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions

AU - Kovacsics, Daniella

AU - Patik, Izabel

AU - Özvegy-Laczka, C.

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: The in vivo fate and effectiveness of a drug depends highly on its absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Organic anion transporting polypeptides (OATPs) are membrane proteins involved in the cellular uptake of various organic compounds, including clinically used drugs. Since OATPs are significant players in drug absorption and distribution, modulation of OATP function via pharmacotherapy with OATP substrates/inhibitors, or modulation of their expression, affects drug pharmacokinetics. Given their cancer-specific expression, OATPs may also be considered anticancer drug targets. Areas covered: We describe the human OATP family, discussing clinically relevant consequences of altered OATP function. We offer a critical analysis of published data on the role of OATPs in ADME and in drug–drug interactions, especially focusing on OATP1A2, 1B1, 1B3 and 2B1. Expert opinion: Four members of the OATP family, 1A2, 1B1, 1B3 and 2B1, have been characterized in detail. As biochemical and pharmacological knowledge on the other OATPs is lacking, it seems timely to direct research efforts towards developing the experimental framework needed to investigate the transport mechanism and substrate specificity of the poorly described OATPs. In addition, elucidating the role of OATPs in tumor development and therapy response are critical avenues for further research.

AB - Introduction: The in vivo fate and effectiveness of a drug depends highly on its absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Organic anion transporting polypeptides (OATPs) are membrane proteins involved in the cellular uptake of various organic compounds, including clinically used drugs. Since OATPs are significant players in drug absorption and distribution, modulation of OATP function via pharmacotherapy with OATP substrates/inhibitors, or modulation of their expression, affects drug pharmacokinetics. Given their cancer-specific expression, OATPs may also be considered anticancer drug targets. Areas covered: We describe the human OATP family, discussing clinically relevant consequences of altered OATP function. We offer a critical analysis of published data on the role of OATPs in ADME and in drug–drug interactions, especially focusing on OATP1A2, 1B1, 1B3 and 2B1. Expert opinion: Four members of the OATP family, 1A2, 1B1, 1B3 and 2B1, have been characterized in detail. As biochemical and pharmacological knowledge on the other OATPs is lacking, it seems timely to direct research efforts towards developing the experimental framework needed to investigate the transport mechanism and substrate specificity of the poorly described OATPs. In addition, elucidating the role of OATPs in tumor development and therapy response are critical avenues for further research.

KW - ADME

KW - Drug-drug interaction

KW - GWAS

KW - hepatic clearance

KW - intestinal absorption

KW - organic anion transporting polypeptides

KW - pharmacogenetics

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85015849297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015849297&partnerID=8YFLogxK

U2 - 10.1080/17425255.2017.1253679

DO - 10.1080/17425255.2017.1253679

M3 - Review article

C2 - 27783531

AN - SCOPUS:85015849297

VL - 13

SP - 409

EP - 424

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 4

ER -